Old Web
English
Sign In
Acemap
>
authorDetail
>
Elisabet Sicart
Elisabet Sicart
Hebron University
Medicine
Glioma
Pathology
Sphingomyelin synthase
Refractory
5
Papers
42
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I study of 2-hydroxyoleic acid (2-OHOA), a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including refractory high grade gliomas/glioblastomas (GBM): Updated results of the expansion.
2016
Journal of Clinical Oncology
Mariane Sousa Fontes
Nikolaos Diamantis
Niamh Coleman
Nina Tunariu
L. Rhoda Molife
Manolo D'Arcangelo
Analia Azaro
Gareth J. Veal
Elisabet Sicart
Ander Urruticoechea
Pablo V. Escribá
Xavier Busquets
Antoine Perier
Vicente Tur
Juanita Lopez
Jordi Rodon Ahnert
Elizabeth R. Plummer
Show All
Source
Cite
Save
Citations (1)
Pivotal role of sphingomyelin synthase (SGMS) expression and activity in glioma patient survival presents a potential therapeutic target.
2015
Journal of Clinical Oncology
Pablo V. Escribá
Xavier Busquets
Victoria Lladó
Desamparados Roda
Begoña Jiménez
R. Molife
Ruth Plummer
Jordi Rodon
Analia Azaro
Elisabet Sicart
Edwin Klumper
Show All
Source
Cite
Save
Citations (0)
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).
2015
Journal of Clinical Oncology
Desamparados Roda
Yvette Drew
Analia Azaro
Alan David Smith
Alastair Greystoke
Elisabet Sicart
Pablo V. Escribá
Xavier Busquets
Victoria Lladó
Vicente Tur
Edwin Klumper
Jordi Rodon Ahnert
L. Rhoda Molife
Ruth Plummer
Show All
Source
Cite
Save
Citations (1)
Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY).
2013
Journal of Clinical Oncology
Jordi Rodon
Michael A. Carducci
Juan Manuel Sepúlveda
Analia Azaro
Emiliano Calvo
Joan Seoane
Irene Brana
Elisabet Sicart
Ivelina Gueorguieva
Ann Cleverly
Sada Pillay
Durisala Desaiah
Michael Lahn
Luis Paz-Ares
Matthias Holdhoff
Jaishri Blakeley
José Baselga
Show All
Source
Cite
Save
Citations (12)
First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.
2011
Journal of Clinical Oncology
J. Rodon Ahnert
J. Baselga
Emiliano Calvo
Joan Seoane
Irene Brana
Elisabet Sicart
Ivelina Gueorguieva
Ann Cleverly
Michael Lahn
Sada Pillay
Matthias Holdhoff
Jaishri Blakeley
Michael A. Carducci
Show All
Source
Cite
Save
Citations (28)
1